Table 4. Comparison of data between the two groups of patients after 1 year of follow-up treatment.
| Total | 24HUPRO (g/L) | ALB (g/L) | CREA (µmol/L) | BUN (mmol/L) | eGFR |
|---|---|---|---|---|---|
| PLA2R −(N = 43) | 0.78 ± 1.10 | 38.21 ± 6.14 | 64.18 ± 14.37 | 5.37 ± 1.50 | 107.77 ± 24.43 |
| PLA2R +(N = 119) | 2.22 ± 2.10** | 35.09 ± 6.97* | 71.47 ± 23.91 | 6.68 ± 2.72* | 105.20 ± 28.09 |
| Pred+CTx | |||||
| PLA2R −(N = 15) | 0.79 ± 1.24 | 37.37 ± 6.80 | 59.54 ± 12.89 | 4.83 ± 1.23 | 118.65 ± 27.28 |
| PLA2R +(N = 55) | 2.24 ± 2.02 | 34.28 ± 6.46 | 63.01 ± 23.25 | 5.75 ± 1.68 | 114.90 ± 26.31 |
| Ped+Csa | |||||
| PLA2R −(N = 9) | 0.21 ± 0.25 | 40.01 ± 4.49 | 72.36 ± 14.42 | 6.25 ± 2.20 | 92.84 ± 17.14 |
| PLA2R +(N = 31) | 2.54 ± 2.45** | 35.02 ± 7.41 | 80.85 ± 23.66 | 7.41 ± 2.62 | 93.74 ± 23.15 |
| Ped+F506 | |||||
| PLA2R −(N = 16) | 1.18 ± 0.61 | 38.18 ± 5.94 | 67.77 ± 15.70 | 5.59 ± 1.55 | 115.02 ± 28.47 |
| PLA2R +(N = 30) | 1.80 ± 1.77 | 36.66 ± 7.08 | 73.19 ± 22.95 | 7.08 ± 3.75 | 114.75 ± 33.04 |
Notes.
eGFR: estimated glomerular filtration rate Compared with the PLa2R− group and the PLA2R+ group, P∗ < 0.05, P∗∗ < 0.01.